ArticleScience signaling2022
Functional and biological heterogeneity of KRAS
Open access · greenAbstract read
In one paragraph
Article in Science signaling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- HRAS promotes mutant NRAS-driven transformation with codon and allele specificity.Science signaling · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.Nature genetics · 2026Article
- Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.Nature genetics · 2026Article
- Quantitative 3D histology reveals localized immune remodeling during early pancreatic cancer progression.Cell press blue · 2026Article
- KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Cancer research · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.Cancer research · 2026Article
- Prognostic Implications of Codon-SpecificJCO precision oncology · 2026Article
- IMPDH and GTP Metabolism in Cancer: Mechanisms, Regulation, and Translational Scope.Cancer science · 2025Review
- Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction.Cancer research communications · 2025Article
- Impact ofHealth science reports · 2025Article
- U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.bioRxiv : the preprint server for biology · 2025Article
- KRAS: the Achilles' heel of pancreas cancer biology.The Journal of clinical investigation · 2025Review
- Evaluating the Effect ofJCO precision oncology · 2025Article
- Review
- Improving outcomes of patients with pancreatic cancer.Nature reviews. Clinical oncology · 2025Review
- Genetics and biology of pancreatic ductal adenocarcinoma.Genes & development · 2025Review
- "Undruggable KRAS": druggable after all.Genes & development · 2025Review
- Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Observational
Corrections and comments
- Commented on by
Authors and funding
21 authors at 7 institutions in 1 country.
Minh V HuynhDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3323-886X
G Aaron HobbsDepartment of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-4751-9681
Antje SchaeferDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2716-9899
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Leiah M CareyDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6103-2933
J Nathaniel DiehlCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7309-0903
Jonathan M DeLibertyDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ryan D ThurmanDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Adelaide R CookeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-4759-5374
Craig M GoodwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-1293-2334
Joshua H CookDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9815-6879
Lin LinDepartment of Molecular and Integrative Physiology, University of Michigan Health System, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6936-4150
Andrew M WatersDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6058-5878
Naim U RashidDepartment of Biostatistics, University of North Carolina at Chapel Hill, NC 27955, USA.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Sharon L CampbellDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0311-409X
Kevin M HaigisDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Diane M SimeonePerlmutter Cancer Center, New York University, New York, NY 10016, USA.ORCID 0000-0001-5142-3087
Costas A LyssiotisDepartment of Molecular and Integrative Physiology, University of Michigan Health System, Ann Arbor, MI 48109, USA.ORCID 0000-0001-9309-6141
Adrienne D CoxDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-4901-2454
Channing J DerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7751-2747
University of North Carolina at Chapel Hill · USGeorge Mason University · USUniversity of Michigan · USBrigham and Women's Hospital · USBroad Institute · USMedical University of South Carolina · USNew York University · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MIntegrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7MThe role of SMAD1 and SATB2 in colon patterningP20GM130457 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Hailong Zhang · 2020 to 2026
$18.7MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MProject 4: The role of codon bias in RAS tumorigenesisP01CA203657 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2016 to 2020
$7.9MTargeting undruggable RAS for cancer treatmentR35CA232113 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2018 to 2024
$6.3MBIOLOGICAL ACTIVITY OF RAS ONCOGENESR01CA042978 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1986 to 2017
$5.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MStructure and Mechanism of G-proteins and cell adhesion proteins in regulation of cell growth and motilityR35GM134962 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sharon L Campbell · 2020 to 2026
$4.2MTissue-specific genetic interactions in cancerR01CA232372 · NCI · DANA-FARBER CANCER INST · PI HAIGIS, KEVIN · 2018 to 2022
$2.9MIdentification of synthetic lethal interactors in pancreatic cancerU01CA199235 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COX, ADRIENNE D, DER, CHANNING J. · 2015 to 2019
$2.5MStromal Fibroblast Autophagy In Tumor Progression and DesmoplasiaR01CA213775 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEBNATH, JAYANTA · 2018 to 2022
$1.9MNCI NIH HHS F30 CA243253NCI NIH HHS F32 CA200313NCI NIH HHS P01 CA203657NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA042978NCI NIH HHS R01 CA175747NCI NIH HHS R01 CA213775NCI NIH HHS R01 CA232372NCI NIH HHS R35 CA232113NCI NIH HHS T32 CA009156NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA199235NIGMS NIH HHS P20 GM130457NIGMS NIH HHS R35 GM134962
Abstract
Missense mutations at the three hotspots in the guanosine triphosphatase (GTPase) RAS-Gly
Indexed as
Carcinoma, Pancreatic DuctalPancreatic NeoplasmsActinsGTP PhosphohydrolasesHumansMutationProto-Oncogene Proteins p21(ras)ActinsGTP PhosphohydrolasesKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.